Posted by Michael Wonder on 19 Apr 2021
European Commission approves second indication of Sarclisa (isatuximab) for relapsed multiple myeloma
19 April 2021 - Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies.
Today, the European Commission approved Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy.
